Clinical characteristics and treatment outcome of acute myeloid leukemia in elderly patients in Korea: A retrospective analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yi, H.G. | - |
dc.contributor.author | Lee, M.H. | - |
dc.contributor.author | Kim, C.S. | - |
dc.contributor.author | Hong, J. | - |
dc.contributor.author | Park, J. | - |
dc.contributor.author | Lee, J.H. | - |
dc.contributor.author | Han, B.R. | - |
dc.contributor.author | Kim, H.Y. | - |
dc.contributor.author | Zang, D.Y. | - |
dc.contributor.author | Kim, S.H. | - |
dc.contributor.author | Park, S.K. | - |
dc.contributor.author | Hong, D.S. | - |
dc.contributor.author | Lee, G.J. | - |
dc.contributor.author | Jin, J.-Y. | - |
dc.date.available | 2020-02-28T18:44:28Z | - |
dc.date.created | 2020-02-12 | - |
dc.date.issued | 2014-06 | - |
dc.identifier.issn | 2287-979X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/12973 | - |
dc.description.abstract | Background: The clinical characteristics of elderly patients with AML differ from those of younger patients, resulting in poorer survival and treatment outcomes. We analyzed retrospectively the clinical data of AML patients 65 years old and above to describe patients' characteristics and treatment patterns, and to define meaningful prognostic factors of survival in the Korean population. Methods: Basic patients' characteristics, clinical outcomes according to treatments, and prognostic factors associated with survival and treatment intensity were examined in a total of 168 patients diagnosed in 5 institutes between 1996 and 2012 as having AML. Results: Herein, 84 patients (50.0%) received high-intensity regimens (HIR), 18 (10.7%) received low-intensity regimens (LIR), and 66 (39.3%) received supportive care (SC) only. The median survival of all patients was 4.5 months; and median survival times with HIR, LIR, and SC were 6.8 months, 10.2 months, and 1.6 months, respectively. Median survival times with HIR and LIR were significantly longer than that with SC (P<0.0001 and P=0.006, respectively). Multivariate analysis identified age, Eastern Cooperative Oncology Group-performance status (ECOG-PS), hemoglobin (Hb) level, and serum creatinine (Cr) level as statistically significant prognostic factors for survival. In the HIR group, prognostic factors for survival were ECOG-PS, Hb level, and C-reactive protein level. Conclusion: Even in elderly AML patients, an intensive treatment regimen could be beneficial with careful patient selection. Further prospective studies designed to identify specific prognostic factors are required to establish an optimal treatment strategy for elderly AML patients. © 2014 Korean Society of Hematology. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | Korean Society of Hematology | - |
dc.relation.isPartOf | Blood Research | - |
dc.title | Clinical characteristics and treatment outcome of acute myeloid leukemia in elderly patients in Korea: A retrospective analysis | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.doi | 10.5045/br.2014.49.2.95 | - |
dc.identifier.bibliographicCitation | Blood Research, v.49, no.2, pp.95 - 99 | - |
dc.identifier.kciid | ART001882806 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-84903523309 | - |
dc.citation.endPage | 99 | - |
dc.citation.startPage | 95 | - |
dc.citation.title | Blood Research | - |
dc.citation.volume | 49 | - |
dc.citation.number | 2 | - |
dc.contributor.affiliatedAuthor | Hong, J. | - |
dc.contributor.affiliatedAuthor | Park, J. | - |
dc.contributor.affiliatedAuthor | Lee, J.H. | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Acute myeloid leukemia | - |
dc.subject.keywordAuthor | Chemotherapy | - |
dc.subject.keywordAuthor | Elderly | - |
dc.subject.keywordAuthor | Prognosis | - |
dc.subject.keywordAuthor | Survival | - |
dc.subject.keywordPlus | anthracycline | - |
dc.subject.keywordPlus | arsenic trioxide | - |
dc.subject.keywordPlus | C reactive protein | - |
dc.subject.keywordPlus | creatinine | - |
dc.subject.keywordPlus | cytarabine | - |
dc.subject.keywordPlus | fludarabine | - |
dc.subject.keywordPlus | hemoglobin | - |
dc.subject.keywordPlus | hydroxyurea | - |
dc.subject.keywordPlus | retinoic acid | - |
dc.subject.keywordPlus | acute granulocytic leukemia | - |
dc.subject.keywordPlus | aged | - |
dc.subject.keywordPlus | article | - |
dc.subject.keywordPlus | cancer patient | - |
dc.subject.keywordPlus | cancer survival | - |
dc.subject.keywordPlus | creatinine blood level | - |
dc.subject.keywordPlus | drug megadose | - |
dc.subject.keywordPlus | female | - |
dc.subject.keywordPlus | health care facility | - |
dc.subject.keywordPlus | hemoglobin blood level | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | Korea | - |
dc.subject.keywordPlus | low drug dose | - |
dc.subject.keywordPlus | major clinical study | - |
dc.subject.keywordPlus | male | - |
dc.subject.keywordPlus | outcome assessment | - |
dc.subject.keywordPlus | retrospective study | - |
dc.subject.keywordPlus | survival time | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.